nature.com
Developing an adaptive platform trial for evaluation of medical treatments for Crohn's disease
Adaptive platform trials could speed testing of multiple Crohn’s treatments and make it easier to compare options, which may shorten the time to find effective therapies. The article outlines design choices and challenges that affect trial quality and how quickly results could reach patients.
Clinicians and researchers running IBD trials, trial designers and funders, patient research advocates, and people interested in faster evaluation of Crohn’s treatments.
What To Know
This Nature Comment summarizes a workshop on designing an adaptive platform (master-protocol) trial for Crohn’s disease. It discusses opportunities and challenges for using multi-arm, multi-stage designs, biomarker stratification, competition for enrollment, and practical lessons from prior platform trials and IBD studies.
The piece is a workshop/report-style commentary rather than a report of trial results. The authors outline why a platform trial could let researchers test multiple treatments faster within a single, flexible protocol and adjust arms over time.
They highlight practical issues such as patient recruitment, use of biomarkers to stratify participants, stopping or adding arms, and ethical/operational considerations. The article references prior platform trials and IBD research and includes input from clinicians, trialists, and patient research champions.
Clinicians and researchers involved in IBD clinical trials, trial designers, funders, and patient advocates interested in research design and accelerating evaluation of new Crohn’s treatments.
This is a commentary/workshop report proposing and discussing trial design approaches; it does not present new patient-level clinical trial results or immediate treatment recommendations. Practical implementation would require subsequent funded prospective trials and regulatory engagement.
This is a workshop/commentary describing trial design options and considerations (biomarker stratification, multi-arm approaches, enrollment challenges). It does not report new efficacy or safety data and does not change clinical care. Further funding, protocol development, and regulatory review would be needed to run such a platform trial.
